Reviews/Anti CGRP Antibodies/Switching CGRP antibodies in non-responders
Real World · CGRP-RW-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
People with migraine who do not respond to one anti-CGRP antibody are sometimes switched to a different one in the same drug class. Several real-world datasets from independent clinics and registries find that a meaningful minority of these non-responders do improve after switching, with roughly one in three reaching a clinically useful reduction in migraine days [6], [20], [27], [31]. The benefit appears largest when the second antibody works through a different mechanism than the first [20], and a laboratory study offers a biological reason why that might be [19]. However, none of the studies had a comparison group receiving no change, so some of the apparent improvement could simply reflect migraine's natural ups and downs rather than the switch itself. The improvement is also modest for many patients and shrinks when people switch more than once [27]. The panel therefore treated the direction of benefit as well supported but the strength and breadth of it as unproven.
Five independent real-world datasets consistently point the same way: after switching antibody, a meaningful minority of prior non-responders improve. [6] reports a 30% response in 32% and a 50% response in 12% of erenumab non-responders switched to a ligand antibody; [20] reports 50% responses in 29.4% at month 3 and 32.9% at month 6; [27] reports a 50% response rate of 50.7% after one switch; [28] found 11 of 24 lack-of-efficacy switches effective; and [31] reports 42.8% achieving a 50% reduction after switching to fremanezumab. [20] further finds the benefit concentrated in switches that change mechanism of action, while no anti-ligand-to-anti-ligand switch reached a greater than 50% reduction. [19] provides a mechanistic rationale, showing the receptor antibody erenumab did not modify sensory thresholds, in contrast to a ligand antibody, suggesting distinct mechanisms. Every one of these datasets is uncontrolled and observational. The contested point: The division is whether the convergent real-world improvement reflects the switch itself or ordinary migraine fluctuation and regression to the mean, since no study has a placebo or sham arm. A second division is scope: the strongest signal is for mechanism-change switches [20], so the broad claim about switching between antibodies rests on narrower evidence than it states.
All 38 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti CGRP Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Every included study ([6],[20],[27],[28],[31]) is uncontrolled (retrospective audit, single-arm cohort, or registry). With no placebo or sham arm, an unknown share of post-switch 'response' is attributable to regression to the mean and natural migraine fluctuation rather than the switch itself.
Effect sizes are modest and threshold-sensitive: [6] reports only 12% achieving ≥50% response, so at a clinically meaningful bar the benefit is small for many switchers.
Where it remains uncertain. All evidence is uncontrolled, the effect is modest at the 50% threshold ([6] 12%), concentrated in mechanism-change switches ([20]), and attenuates on a second switch ([27]).
Aleatory
Migraine frequency varies spontaneously, so some post-switch improvement in uncontrolled cohorts reflects regression to the mean rather than the switch.
The load-bearing papers from a corpus of 38, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct primary evidence that a subset of erenumab non-responders benefit from switching antibody class.
“The switch from erenumab to a CGRP-mAb led to a ≥30% response in one-third (32%) of the patients after three treatment cycles. A ≥50% response was achieved in 12% of the patients.”
Panel auditInternal validity: medium · scope of inference: Erenumab (receptor) non-responders switched to a ligand mAb; benefit concentrated in non-daily headache.Key limitations: small n · retrospective · no comparator
Provides mechanistic rationale (distinct receptor vs ligand action) for why class switching can rescue non-responders.
“real-life data demonstrate that up to 30% of non-responders to one class exhibit a positive response to switching classes, indicating different mechanisms.”
Panel auditInternal validity: medium · scope of inference: Mechanistic difference between receptor and ligand mAbs via sensory testing.Key limitations: surrogate QST endpoint · no clinical switch outcome
Confirms benefit of switching and localises it to mechanism-change switches, qualifying the claim's scope.
“A ≥ 50% response was achieved in 29.4% (25/85) of patients at month 3 and 32.9% (28/85) at month 6. One-third of patients whose switch included a change in mechanism of action responded, while none of those who underwent anti-ligand to anti-ligand switch showed a reduction of MHDs >50%.”
Panel auditInternal validity: medium · scope of inference: CM/HFEM patients switching between mAbs; benefit greater with anti-receptor vs anti-ligand mechanism change.Key limitations: uncontrolled · single centre
3 of 38 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, independently replicated real-world benefit supports the claim, but absence of controlled data and a modest, scope-limited effect cap confidence below the Established and Likely-upper range.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No controlled switch trial. Every supporting study is uncontrolled, so observed benefit cannot be separated from regression to the mean and natural fluctuation. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised, sham- or continuation-controlled trial of switching versus continuing the first antibody in confirmed non-responders.
Open question: Is the post-switch improvement caused by the switch or by regression to the mean and natural migraine fluctuation? Why it is still open: No corpus study has a placebo, sham or continuation control arm ([6], [20], [27], [28], [31]).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19